[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100524514":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":24,"centralContacts":28,"locations":18,"responsibleParty":37,"collaborators":18,"id":40,"slug":41,"hasResults":42,"nctId":43,"briefTitle":44,"officialTitle":44,"acronym":45,"eligibilityCriteria":46,"healthyVolunteers":47,"sex":48,"minAge":49,"maxAge":50,"enrollmentInfo":51,"targetDuration":18,"studyType":54,"phases":55,"briefSummary":57,"conditions":58,"keywords":61,"overallStatus":65,"whyStopped":18,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":18},{"fullName":5,"class":6},"University of Maryland, Baltimore","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"ACUMEN guided resuscitation protocol","EXPERIMENTAL","Fluid resuscitation and hemodynamic management will be guided by ACUMEN based off a protocol.",[13],"Other: Goal Directed Fluid Therapy",{"label":15,"type":16,"description":17,"interventionNames":18},"Standard of care resuscitation","NO_INTERVENTION","Fluid resuscitation will be guided by standard monitors (urine output, blood loss, transesophageal echocardiography).",null,[20],{"type":6,"name":21,"description":22,"armGroupLabels":23,"otherNames":18},"Goal Directed Fluid Therapy","Fluid administration and hemodynamic management guided with the assistance of Edwards Lifesciences ACUMEN monitor",[9],[25],{"name":26,"affiliation":5,"role":27},"Reney A Henderson, MD","PRINCIPAL_INVESTIGATOR",[29,33],{"name":26,"role":30,"phone":31,"phoneExt":18,"email":32},"CONTACT","4103283961","rhenderson@som.umaryland.edu",{"name":34,"role":30,"phone":35,"phoneExt":18,"email":36},"LaToya Stubbs","4103289951","lstubbs@som.umaryland.edu",{"type":27,"investigatorFullName":38,"investigatorTitle":39,"investigatorAffiliation":5,"oldNameTitle":18,"oldOrganization":18},"Reney Henderson","Assistant Professor","100524514","early-biomarker-kidney-injury-assessment-after-acumen-directed-fluid-management-in-cardiac-surgery-100524514",false,"NCT06109714","Early Biomarker Kidney Injury Assessment After Acumen Directed Fluid Management in Cardiac Surgery","BE-KIND","Inclusion Criteria:\n\n* Adult patients undergoing cardiopulmonary bypass\n* Procedure coronary artery bypass grafting, aortic valve replacement, or both\n\nExclusion Criteria:\n\n* Patients \\\u003C 18 years old\n* Emergent surgery\n* Preoperative kidney disease (Cr \\> 2.0 or on renal replacement therapy)\n* Ejection fraction \\\u003C 40%\n* Incomplete data in medical record",true,"ALL","18 Years","90 Years",{"count":52,"type":53},100,"ESTIMATED","INTERVENTIONAL",[56],"NA","This study is to assess the benefits of goal-directed fluid management with ACUMEN in cardiac surgical patients and its impact on cardiac surgery-induced kidney injury.",[59,60],"Renal Injury","Acute Kidney Injury",[62,63,64],"Cardiac Surgery","Cardiac Surgery Induced Kidney Injury","Kidney Biomarkers","NOT_YET_RECRUITING","2026-06-19",{"date":68,"type":69},"2026-06-23","ACTUAL",{"date":71,"type":53},"2026-09-01",{"date":73,"type":53},"2030-12-31",{"name":5,"class":6}]